Lupin receives EIR from USFDA for its Aurangabad manufacturing facility
May 3, 2024
Source: https://www.lupin.com/lupin-receives-eir-from-us-fda-for-its-aurangabad-manufacturing-facility/
96
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Lupin has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Aurangabad manufacturing facility.
The inspection was conducted from March 6 to March 15, 2024. The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).
Nilesh Gupta, Managing Director, Lupin said, “We are pleased to receive the EIR with VAI status from the USFDA as an outcome of the recent inspection of our Aurangabad facility. It is a testament to our commitment to consistently upholding the highest standards of compliance and providing high-quality healthcare solutions to patients worldwide.”
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Over 5.7 billion! China’s dual antibody ADC goes global+1 November 21, 2024
- Is Jingtai Technology once again breaking through the “first AI pharmaceutical stock” halo and shedding? November 21, 2024
- Yangqi Medical Chip completes tens of millions of yuan in Pre-A round financing November 21, 2024
- Endovascular stent approved through priority green channel November 21, 2024
- Well-known products of foreign companies such as AZ, Eli Lilly, and Sanofi were disqualified November 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
